A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 19 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 16th largest by enrollment, is one of 3 that started in 2021, is one of 19 in phase 3, and was the 15th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2021.
This study's enrollment of 82 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 120 across the 23 interventional studies. Of the 18 that completed or were terminated, 17 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 23 have an industry lead sponsor. The 4 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 54th largest by enrollment of the 116 interventional ones that give a count, is one of 6 that started in 2021, is one of 62 in phase 3, and was the 100th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
2 of the studies testing elexacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity using wearable technology in CF participants.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received ELX 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period approximately 13 weeks.
Drug: ELX/TEZ/IVA · Drug: IVA
Drug pages: Elexacaftor · Tezacaftor · Ivacaftor
Fixed dose combination (FDC) tablet for oral administration.
Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor
Tablet for oral administration.
Also known as: VX-770, ivacaftor
Percent Reduction From Baseline in Cough Frequency (Cough Events Per Day) to the Average of Week 8 Through Week 12
Percent reduction in cough frequency was analyzed with a mixed effects model for repeated measures (MMRM), with change from baseline at each post-baseline visit on the natural log scale as the dependent variable. The percent reduction was estimated as 100% × (1-exponential form of LS mean change estimate from the MMRM).
Time frame: Baseline, Week 8 through Week 12
Absolute Change From Baseline in Total Step Count Per Day to the Average of Week 8 Through Week 12
Time frame: Baseline, Week 8 through Week 12
| Milestone | ELX/TEZ/IVA |
|---|---|
| Started | 82 |
| Completed | 80 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Enrolled but never dosed | 1 |
Percent reduction in cough frequency was analyzed with a mixed effects model for repeated measures (MMRM), with change from baseline at each post-baseline visit on the natural log scale as the dependent variable. The percent reduction was estimated as 100% × (1-exponential form of LS mean change estimate from the MMRM).
| percent reduction | ELX/TEZ/IVA |
|---|---|
| Percent Reduction From Baseline in Cough Frequency (Cough Events Per Day) to the Average of Week 8 Through Week 12 | 91.7 (89.2 to 93.6) |
| step count per day | ELX/TEZ/IVA |
|---|---|
| Absolute Change From Baseline in Total Step Count Per Day to the Average of Week 8 Through Week 12 | 637.56 (298.16 to 976.96) |
Collected over Day 1 up to Week 17. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ELX/TEZ/IVA | 0/81 (0%) | 2/81 (2.5%) | 56/81 (69.1%) |
| Event | ELX/TEZ/IVA |
|---|---|
| PancreatitisGastrointestinal disorders | 1/81 |
| AnxietyPsychiatric disorders | 1/81 |
| Event | ELX/TEZ/IVA |
|---|---|
| HeadacheNervous system disorders | 14/81 |
| COVID-19Infections and infestations | 13/81 |
| NasopharyngitisInfections and infestations | 13/81 |
| DiarrhoeaGastrointestinal disorders | 11/81 |
| Abdominal painGastrointestinal disorders | 8/81 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 8/81 |
| Abdominal pain upperGastrointestinal disorders | 7/81 |
| Upper respiratory tract infectionInfections and infestations | 7/81 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/81 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 5/81 |
All participants who received at least one dose of the study drug during the treatment period were included in the baseline analysis.
| Age, Continuous(years) | ELX/TEZ/IVA |
|---|---|
| Mean | 25.7 ± 9.6 |
| Sex: Female, Male(Participants) | ELX/TEZ/IVA |
|---|---|
| Female | 37 |
| Male | 44 |
| Ethnicity (NIH/OMB)(Participants) | ELX/TEZ/IVA |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 78 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | ELX/TEZ/IVA |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 81 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Ran from Oct 2021 to primary completion in Jul 2022, 9 months.
Results were first posted in Oct 2023, 1 year 2 months after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 9 months is below that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →